Descripción

Clinical or preclinical efficacy data from nanostructured 5-alpha reductase inhibitor formulations applied to alopecia models. Hair regrowth parameters and follicular drug concentrations indicate improved therapeutic outcomes.

Figure 8

Chart

Source Paper

Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle.

Pharmaceutics (2022)

PMID: 35214018

DOI: 10.3390/pharmaceutics14020286

Cite This Figure

![Figure 8: Clinical or preclinical efficacy data from nanostructured 5-alpha reductase inhibitor formulations applied to alopecia models. Hair regrowth parameters and follicular drug concentrations indicate improved therapeutic outcomes.]()

> Source: Silvia Tampucci et al. "Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to t." *Pharmaceutics*, 2022. PMID: [35214018](https://pubmed.ncbi.nlm.nih.gov/35214018/)

<figure>
  <img src="" alt="Clinical or preclinical efficacy data from nanostructured 5-alpha reductase inhibitor formulations applied to alopecia models. Hair regrowth parameters and follicular drug concentrations indicate improved therapeutic outcomes." />
  <figcaption>Figure 8. Clinical or preclinical efficacy data from nanostructured 5-alpha reductase inhibitor formulations applied to alopecia models. Hair regrowth parameters and follicular drug concentrations indicate improved therapeutic outcomes.<br>  Source: Silvia Tampucci et al. "Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to t." <em>Pharmaceutics</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35214018/">35214018</a></figcaption>
</figure>

Evidencia relacionada

Minoxidil para Alopecia Androgenética

Calificación A · 299 estudios

Finasteride para Alopecia Androgenética

Calificación A · 206 estudios

Dutasteride para Alopecia Androgenética

Calificación A · 99 estudios